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Strategies for building reference
standards for autoantibodies
Joanna Sheldon 1* and Alessandra Dellavance 2
1 Protein Reference Unit, St George’s Hospital, London, UK, 2 Research and Development Division, Fleury Medicine and
Health Laboratories, São Paulo, Brazil
Producing robust, certified, traceable reference material for autoantibody testing is a
vital element in maintaining the validity of results that are generated in the daily clinical
laboratory routine. This is a huge challenge because of the high number of variables
involved in the detection and measurement of the autoantibodies. The production of such
materials is time consuming and needs rigorous attention to detail; this is best achieved
by an overarching independent body who will oversee the process in a “not for profit”
manner. Much effort has been made to build international standards for quantitative and
qualitative assays based on monoclonal antibodies, obtained from affinity purification
and plasmapheresis. The big challenge is to respect individual differences in immune
response to the same antigen. A promising ongoing initiative is the construction of pools
with monospecific samples from different individuals.
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Introduction
The availability of standards or reference materials is central to the generation of reliable and
interpretable laboratory which, in turn are vital for accurate patient diagnosis and management.
Results from different clinical laboratory measurement procedures should be equivalent within
clinically meaningful limits. The characteristics of an ideal reference material are shown in Table 1.
Standardization of invariable analytes that can be prepared as pure substances, e.g., glucose, is
straightforward. In contrast, analytes that present subtle variation from one individual to another
poise a significant challenge to the building of reference material. This is the case for antibodies,
where each individual mounts a polyclonal collection of immunoglobulins that share the property of
binding to the antigen of interest. However, they differ regarding the target epitopes, avidity, isotype,
etc. This is further complicated by the fact that the multiple available methods for autoantibody
detection vary in the ability of detecting different types of immunoglobulins. When the definition
of the analyte and the analytical methods are variable, the production of reference material is
inadequate (1).
The production of protein standards is more complex because the isolation, purification, and
drying steps may all contribute to degradation of the proteinmaking it incomparable with the native
protein that would be seen in a clinical sample. Furthermore, almost all peptides and proteins in
biological fluids show some degree of molecular heterogeneity and the purification methods sub-
fractionate these forms. For simple, single chain proteins, recombinant material may be appropriate
although care and attention must be paid to any allotypic variation that may exist but also the minor
molecular characteristics, e.g., the glycosylation that may differ between native and recombinant
proteins (2).Asmentioned above, antibodies or immunoglobulins have a greater degree ofmolecular
heterogeneity than other proteins due to the inherent variability of the antigen binding site, the
presence of multiple chains, the presence of immunoglobulin subclasses and variations in affinity
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TABLE 1 | Characteristics of a reference material.
Characteristic Explanation
Homogeneous Low and stated variability in concentration of the
measurand between vials of the material
Traceable Related to a higher-order reference material (usually national
or international) through an unbroken chain of comparisons,
all with stated uncertainty
Commutable The characteristic of a reference material to behave in a
comparable way to the samples (relevant to the intended
use of the reference material)
Available There must be sufficient material that is readily available to
relevant laboratories or companies over a time period of
approximately 5–10 years
Stable The material must be stable over its expected life-span
Certified Ideally, reference material should be certified with stated
uncertainties of the various characteristics
Safe Chemically and biologically safe (including tested as
negative for HIV and Hepatitis B)
Ethical Where relevant, samples from patients have been collected
ethically and with appropriate agreement from the patients
and avidity of antibody binding both between and within indi-
viduals. An immune stimulus may drive one clone, a few clones
or many clones of B cells to produce antibody generating a mon-
oclonal, oligoclonal, or polyclonal response, respectively. Finally,
the antigen to which we are trying tomeasure antibodies is usually
a protein with its own variability and molecular heterogeneity.
This feature of antibodies is critical to the standardization issue
because different methodological platforms vary with respect to
the types of immunoglobulins and types of antibody–antigen
interactions they are able to detect.
Considering all these issues, alongside the analytical aspects
of the detection and quantification of autoantibodies, it is not
surprising that standardization of autoimmune serology is a
major challenge. It is likely that to have truly robust quantification
of autoantibodies, the antigen in question will need to be carefully
defined. This may come down even to the molecular domain
level as it is reported that antibodies to certain parts of a molecule
are associated with less severe disease (3). The analytical platform
may also need to be defined as newer methods and technologies
are introduced, which adds another source of variation to the
analytical process (4). Some methodological platforms favor the
presentation of native and conformational epitopes whereas some
others preferentially offer denatured linear epitopes. The long-
term goal is standardization of clinically relevant antibodies to
well characterized autoantigens by thoroughly defined methods
but this will be a “step-wise” process based on clinical need and
scientific evidence. The most appropriate place to start, however,
is with the introduction of reference or standardization material
for the antibody.
The majority of clinically relevant autoantibodies are of the
IgG class and the starting material for making standards for
autoimmune serology will be a biological matrix, e.g., serum (or
plasma) from patients known to have antibodies directed against
the chosen antigen. Ideally, the autoantibody standards should be
obtained from patients with the congnate autoimmune disease;
however, the most important factor will be how the (candidate)
reference material behaves in comparison to a large panel of sam-
ples from patients with and without a stated autoimmune disease
or autoantibody. The clonality of autoantibodies is poorly investi-
gated with reports of the presence of monoclonal, polyclonal, and
oligoclonal antibodies. Hawa et al. report that in diabetic patients,
glutamic acid decarboxylase (GAD) and IA-2 antibodies were
usually subclass restricted to IgG1 and were polyclonal although
IgM, IgG3, and IgE isotypes were also detected (5). Similarly,
Eisenberg et al. report that anti-Sm antibodies in patients with
systemic lupus erythematosus are mainly of the IgG1 subclass but
with the kappa to lambda light chain distribution similar to that
seen in normal polyclonal serum (6).
The Use of Pooled Sera for Reference
Standards for Autoantibodies
Autoantibodies are present in samples from normal patients but
usually these are at very low concentration. In contrast, high
titer and high affinity autoantibodies are present in patients with
certain autoimmune diseases. Samples from such patients are an
important source of material to be developed into reference mate-
rial. The strategy of obtaining large volumes of serum or plasma
from a single patient has been successfully used for the establish-
ment of reference material for several autoantibody specificities
related to systemic autoimmune rheumatic diseases (7). Plasma-
pheresis has been used to rapidly remove antibodies from patients
and the serum is regarded as the “waste product” that would oth-
erwise be discarded. However, plasmapheresis is less commonly
indicated now making this source of samples ethically question-
able. The use of single patient material also raises the concern that
the autoantibody profile may not be representative of the hetero-
geneity of patients with that autoimmune disease. Pooling serum
samples from a number of patients is likely to generate a material
with a wide range of antigenic specificities and likely to be repre-
sentative of the antibodies that would be seen in many patients.
It is worth noting that the production of a certified International
Reference Material would be in the order of 2500 vials each con-
taining 1mL of serum, therefore the starting volume of basemate-
rial needs to be 3–3.5 L. In order to generate this volume of base
material, approximately 150 patients would need to give 50mL of
whole blood, so any initiative to produce autoantibody reference
materials pooled from patient samples would need to be a collab-
oration between different centers or even different countries.
The use of pooled serum for protein standardization is
well established; the certified reference preparation ERM-
DA470k/IFCC is used across the world for standardization of
plasma protein concentrations, e.g., total IgG, IgA, and IgM
concentrations (8). However, this material is based on samples
from normal donors rather than samples containing abnormal
concentrations of analytes. Samples from patients with systemic
autoimmune rheumatic diseases often show high concentrations
of rheumatoid factor or immune complexes, which may cause
interference to varying degrees in immunoassay. Mixing samples
from different patients can increase the possibility of interference;
therefore, the samples included in the pools should be carefully
monitored.
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The Use of Affinity Purified Material for
Reference Standards for Autoantibodies
Affinity purification is a powerful technique that can enrich or
purify a protein from a complex mixture of proteins. In the
context of preparing reference material for autoantibodies, this
technique would select the antibodies that bind to the chosen
antigen. The antigen (appropriately purified) is chemically immo-
bilized to a support medium, e.g., gel or resin micro-beads packed
into a column. The beads are very porous, so proteins can flow
freely in and around them providing a huge surface area for
interaction between the antigen and the antibodies. The initial
binding stage is usually done at physiologic ionic strength and
pH then, after a washing stage to remove all unbound proteins,
the bound analyte (in this case the autoantibodies) is eluted
off the column by dissociating the antibody–antigen binding by
changing the pH.
Affinity purification will often remove the potential interfer-
ing substances such as rheumatoid factor from the base serum.
Material can be made from a number of patient donors and
this may be blended to optimize the behavior of the reference
material and give long-term consistency. However, there is still a
requirement for large volumes of patient serum as the rawmaterial
plus significant amounts of the relevant antigen in an appropriate
conformational state. The facilities required to produce sufficient
affinity purified autoantibodies for a robust “long-term” reference
material will be sophisticated and expensive.
There is, however, a very important role of affinity purified
autoantibodies; whatever we produce as a potential reference
material will need to be value assigned, i.e., to be given a con-
centration of the analyte in units traceable to a higher-order
metrologically based reference measurement system. When we
measure autoantibodies, we are actually measuring the amount of
IgG that binds onto a defined antigen and ERM-DA470k/IFCC
is the certified reference preparation for measurement of IgG
in serum. An affinity purified preparation of an autoantibody
can be used as a calibrant to assign values of IgG to reference
materials produced from pooled serum or serum from other
sources. This is the process that has been used for value assign-
ment of the new International Reference Preparation for IgG
antibodies to myeloperoxidase, which has now been certified as
ERM-DA476/IFCC (9).
The Use of Monoclonal Cell Cultures for
Reference Standards for Autoantibodies
From the homogeneity point of view, monoclonal antibodies
present a very attractive base material for the production of stan-
dards. The standard producers should have the legal and ethical
right to use the cell line for production of material but if the
cell line does produce a robust and stable monoclonal antibody,
relatively large amounts of thematerial will be able to be produced
at a relatively low cost with long-term consistency. Unlike pooled
serum or even plasmapheresis material, monoclonal antibodies
should be intrinsically free of interfering substances. However, a
monoclonal antibody may not be representative of the spectrum
of antibodies seen in patients. Another concern is that the amount
of antibody neededmay challenge even themost sophisticated cell
line production capabilities; if we needed 2500 vials of reference
material each containing 1mL of matrix with an antibody con-
centration of 50mg/L, we would need 125 g of the monoclonal
autoantibody.
Ongoing Initiatives
Along with the development of reference material for quantitative
assays, some groups are working on improving the standardiza-
tion of qualitative testing, e.g., indirect immunofluorescence (IIF)
for antinuclear antibodies. Mariz et al. showed that the nuclear
dense fine speckled (DFS) pattern is the most frequent (45.8%)
positive ANA pattern among normal donors when tested using
indirect IIF by HEp-2 cells as a substrate (10). The DFS pattern
is strongly associated with antibodies to LEDGF/p75 and these
are primarily seen as a diagnostically non-specific finding in
healthy subjects (10, 11). The recognition of the DFS pattern
is an important skill in the ANA testing procedure as correct
identification and appropriate reporting should limit misinterpre-
tation by the physician and inappropriate and damaging inves-
tigation for the patients. The availability of a quality control or
reference material for this pattern, which was readily available,
is therefore highly desirable. A 1-L pool of samples from 560
individuals showing high titer (positive at 1/640) of the DFS
pattern has been collected. This pool has been evaluated to ensure
that it preserves the individual heterogeneity of the immune
response to the target antigen and represents an opportunity for
a proof of concept for the use of pooling samples to construct
an autoantibody international standard to be processed on IIF
ANA-HEp-2 assay, ELISA, and western blot. This standard shall
be available in 2015 by the Autoantibody Standardizing Com-
mittee affiliated with the International Union of Immunology
Societies (IUIS) at http://asc.dental.ufl.edu/ReferenceSera.html
#text.
The process for collecting the anti-DFS samples has been tightly
controlled. All samples are coded and kept at  80°C. Individual
samples were validated by IIF ANA-HEp-2 assay, anti-LEDGF
chemiluminescent assay (BioFLASH, Inova Diagnostics, Inc.).
Pentapools (comprising five samples) were sequentially assem-
bled and validated in the BioFLASH assay. Icosapools (com-
prising four validated pentapools) were sequentially assembled
and validated as above. Centumpools (comprising five validated
icosapools) were sequentially assembled and validated as above.
Finally, five validated centumpools were assembled to consti-
tute the final pool. Pentapools, icosapools, centumpools, and the
megapools were also validated in indirect immunofluorescence in
HEp-2 cells and in western blot. The semi-quantitative chemilu-
minescent assay gave us the opportunity to compare the expected
and the obtained anti-LEDGF reactivity in all pool combina-
tions. The mean of 425 serum samples was 434.3 (26.1–3080.0)
chemiluminescent units (CU) and the mean of 85 pentapools
was 484.4 (60.4–25317) CU. Most pools behaved as expected,
yielding reactivity quantitatively compatible with the mean of the
individual sera, but there were some unexpected deviations in
some cases. However, in no case was the deviation significant
enough to prevent undisputable anti-LEDGF/p75 reactivity in all
methodological platforms.
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These results support the development of large pools with
multiple individual samples for the establishment of international
standards for qualitative tests. However, the extrapolation of this
model to other autoantibody specificities must be validated by
appropriate studies.
The development of robust standards or certified reference
materials is a huge challenge. Success will depend on collabora-
tion between the clinicians, patients, scientists, and the corporate
sector with an overarching independent group maintaining the
integrity of the process.
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